T

he next time you view promotional information about a prescription drug on your smartphone, don’t be surprised if the risk information is harder to find than the benefits.

A new study by Food and Drug Administration staffers found that risks are not as “equally prominent and accessible” on smartphones, suggesting that many drug makers are not complying with regulations about providing information with so-called “fair balance.” The study was published earlier this week in the Journal of Medical Internet Research.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy